AAV-DJ Anti-CD19 CAR (CD19 ScFv-CD8-4-1BB-CD3ζ)

Products from BPS Bioscience require a minimum order value above 400€

Applications: Positive control for anti-CD19 CAR evaluation in T cells.Transduction optimization experiments.Generate anti-CD19 CAR-T cells (for research use only, not for therapeutic purposes).

Background: Adeno-Associated Virus-DJ (AAV-DJ) is a synthetic serotype made from eight different wild-type AAV serotypes (AAV2, 4, 5, 8, 9, avian, bovine, and goat AAV) using DNA shuffling. These modifications allow the AAV-DJ serotype to exhibit improved transduction efficiency in vitro and in vivo and infect a broader range of cell types compared to the wild-type serotypes.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Description: The AAV-DJ Anti-CD19 CAR (CD19 ScFv-CD8-4-1BB-CD3ζ) is an AAV-DJ encoding the ScFv portion of anti-CD19 (clone FMC63) linked to the 2^nd generation CAR (Chimeric Antigen Receptor) containing the CD8 hinge, 4-1BB and CD3ζ signaling domains, under the control of a EF1α promoter (Figure 1).

Figure 1. Schematic representation of AAV-DJ Anti-CD19 CAR (CD19 ScFv-CD8-4-1BB-CD3ζ). The diagram indicates the components of the anti-CD19 CAR (ScFv-CD8-4-1BB-CD3ζ).

Formulation: AAV was produced in HEK293 cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68. Viral particles can be packaged in custom formulations by special request, for an additional fee.

Purification: Purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium #21005-1L). The purity will vary with each lot; the exact value will be provided with each shipment.

Storage Stability: AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle

Supplied As: Two vials (50 µl x 2) of AAV at a titer ?1 x 10¹² vector genomes/ml. The titer is determined by qPCR and varies with each lot; the exact value will be provided with each shipment

Warnings: Avoid freeze/thaw cycles

Biosafety Level: BSL-1

• Artikelnummer: BPS82092
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 82092
• Verpackungseinheit: 50 µl x 2
• Mengeneinheit: PAK